Related references
Note: Only part of the references are listed.Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Gail D. Lewis Phillips et al.
CLINICAL CANCER RESEARCH (2014)
Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization
Bohua Li et al.
CANCER RESEARCH (2013)
Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancer
Zhongzhen Guan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
Paul E. Goss et al.
LANCET ONCOLOGY (2013)
Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis
Toshiyuki Minami et al.
SCIENTIFIC REPORTS (2013)
HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation
David B. Vaught et al.
CANCER RESEARCH (2012)
Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification
Hideo Tomioka et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy
Xuejun Fan et al.
BREAST CANCER RESEARCH (2012)
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
S. Iqbal et al.
ANNALS OF ONCOLOGY (2011)
Stimulated γδ T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer
Aude-Helene Capietto et al.
JOURNAL OF IMMUNOLOGY (2011)
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
Maurizio Scaltriti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation
Yen-Chao Wang et al.
BREAST CANCER RESEARCH (2011)
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Y. Kataoka et al.
ANNALS OF ONCOLOGY (2010)
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
Britta Weigelt et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
Dhara N. Amin et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
The effects of trastuzumab on the CD4+CD25+FoxP3+and CD4+IL17A+T-cell axis in patients with breast cancer
C. Horlock et al.
BRITISH JOURNAL OF CANCER (2009)
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
M. Toi et al.
BRITISH JOURNAL OF CANCER (2009)
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Linda C. Benavides et al.
CLINICAL CANCER RESEARCH (2009)
A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
Howard A. Burris et al.
CLINICAL CANCER RESEARCH (2009)
Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Evelyn Yao et al.
CLINICAL CANCER RESEARCH (2009)
Autopsy Diagnosis of Progressive Multifocal Leukoencephalopathy With JC Virus-Negative CSF After Cord Blood Stem-Cell Transplantation
Sarah I. Sheikh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of Food on Bioavailability of Lapatinib: Useful Data, Wrong Conclusion
Ian F. Tannock
JOURNAL OF CLINICAL ONCOLOGY (2009)
Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab
M. Pickl et al.
ONCOGENE (2009)
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Natalia Jura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2008)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
Si Tuen Lee-Hoeflich et al.
CANCER RESEARCH (2008)
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Alessandra Beano et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab
Shizhen Emily Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
Dongwei Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes
Z. Cai et al.
ONCOGENE (2008)
Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: Hold back, we are not there yet
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
Augmented HER-2-Specific immunity during treatment with trastuzumab and chemotherapy
Clare Taylor et al.
CLINICAL CANCER RESEARCH (2007)
Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T
J. Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Timeline - Insights from transgenic mouse models of ERBB2-induced breast cancer
Josie Ursini-Siegel et al.
NATURE REVIEWS CANCER (2007)
CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients
Sonia A. Perez et al.
CLINICAL CANCER RESEARCH (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
WL Xia et al.
ONCOGENE (2004)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
R Gennari et al.
CLINICAL CANCER RESEARCH (2004)
Enhancement of the p2KIP1-mediated antiproliferative effect of trastuzumab (herceptin) on her2-overexpressing tumor cells
R Marches et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
